Sponsor

Hipra Scientific S.L.

Spain Avinguda Selva 135, 17170, Spain

About the sponsor

Hipra Scientific S.L. focuses on SARS-CoV-2 vaccination strategies in adults and adolescents, with research centred on heterologous booster use and adapted recombinant protein vaccine candidates for COVID-19.

Booster immunisation in previously vaccinated populations
Safety and tolerability evaluation
Immunogenicity against emerging variants

The sponsor’s clinical work includes adults with prior mRNA vaccine exposure and adolescents receiving booster protection after primary vaccination.

About Specializations

Hipra Scientific S.L. runs clinical trials in conditions such as COVID-19, Influenza, among others.

All trials

Ongoing trials

Clinical trials registered by this sponsor – none is enrolling right now.

Quick filters

5 clinical trials

COVID-19

Not recruiting

Registered drugNo placebo

Safety and Immunogenicity of SARS-COV-2 VIRUS, VARIANT LP.8.1, SPIKE PROTEIN, RECEPTOR BINDING DOMAIN FUSION HOMODIMER Vaccine in Adults with COVID-19

Registered drugNo placebo

Spain

Participants:18–64 years · 65+ years · Healthy volunteers
Substances:SARS-COV-2 VIRUS, VARIANT LP.8.1, SPIKE PROTEIN, RECEPTOR BINDING DOMAIN FUSION HOMODIMER
Sponsor:Hipra Scientific S.L.

Contact Research Centre

COVID-19

Not recruiting

Registered drugNo placebo

A study to test the safety and immune response of PHH-1V111 vaccine against COVID-19 variants in adults

Registered drugNo placebo

Spain

Participants:65+ years · Healthy volunteers
Sponsor:Hipra Scientific S.L.

Contact Research Centre

COVID-19

Not recruiting

Registered drugNo placebo

Study on the Safety and Immune Response of PHH-1V81 Booster for Adults Vaccinated Against COVID-19

Registered drugNo placebo

Spain

Participants:18–64 years · 65+ years · Healthy volunteers
Substances:Raxtozinameran
Sponsor:Hipra Scientific S.L.

Contact Research Centre

COVID-19

Not recruiting

Registered drugNo placebo

Study on the Safety and Immune Response of BIMERVAX as a COVID-19 Booster in Adolescents Aged 12 to 17 Years

Registered drugNo placebo

Spain

Participants:0–17 years · Healthy volunteers
Substances:SARS-COV-2 VIRUS, VARIANTS B.1.351-B.1.1.7, SPIKE PROTEIN, RECEPTOR BINDING DOMAIN FUSION HETERODIMER
Sponsor:Hipra Scientific S.L.